Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/38123
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCruzado, Josep M
dc.contributor.authorLauzurica, Ricardo
dc.contributor.authorPascual, Julio
dc.contributor.authorMarcen, Roberto
dc.contributor.authorMoreso, Francesc
dc.contributor.authorGutierrez-Dalmau, Alex
dc.contributor.authorAndrés, Amado
dc.contributor.authorHernández, Domingo
dc.contributor.authorTorres, Armando
dc.contributor.authorBeneyto, Maria Isabel
dc.contributor.authorMelilli, Edoardo
dc.contributor.authorManonelles, Anna
dc.contributor.authorArias, Manuel
dc.contributor.authorPraga Terente, Manuel
dc.date.accessioned2019-06-28T18:45:45Z-
dc.date.available2019-06-28T18:45:45Z-
dc.date.issued2018-01
dc.identifier.citationKidney Int Rep.2018 Jan;(3)1:122-132
dc.identifier.urihttps://hdl.handle.net/20.500.12530/38123-
dc.description.abstractSecondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications. This study was designed to evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in de novo kidney allograft recipients.
dc.language.isoeng
dc.rightsopenAccess-
dc.subjecthyperparathyroidism
dc.subjectkidney transplantation
dc.subjectparicalcitol
dc.subjectvitamin D
dc.titleParicalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients.
dc.typeArtículo
dc.identifier.pubmedID29340322
dc.format.volume3
dc.format.page122-132
dc.identifier.e-issn2468-0249
dc.identifier.journalKidney international reports
dc.identifier.doi10.1016/j.ekir.2017.08.016
dc.format.number1
dc.identifier.pmcPMC5762965
dc.pubmedtypeJournal Article
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC5762965.pdf497.64 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.